Subscribe

Articles

Patient-Centered Clinical Pathways Should Incorporate the Patient’s Voice
Patient-Centered Clinical Pathways Should Incorporate the Patient’s Voice
By Chase Doyle
Clinical Pathways
TON - December 2019, Vol 12, No 6
San Diego, CA—Patient-centered clinical pathways may hold the promise of truly personalized medicine, improving value-based care and clinical outcomes. However, according to Cary P. Gross, MD, Director, Cancer Outcomes, Public Policy and Effectiveness Research Center, Yale School of Medicine, New Haven, CT, substantial challenges still stand in the way of including the patient’s voice in these pathways. Read More ›
Noninvasive Molecular Diagnosis Using Circulating DNA Sequencing Improves Outcomes in Cholangiocarcinoma Management
Noninvasive Molecular Diagnosis Using Circulating DNA Sequencing Improves Outcomes in Cholangiocarcinoma Management
By Wayne Kuznar
Cholangiocarcinoma
TON - December 2019, Vol 12, No 6
Diagnosis of cholangiocarcinoma (CCA) is often identified at a late stage. Analyzing the tumor-specific mutation profile of a patient with CCA can improve the diagnosis and treatment for the individual patient. The molecular profile of CCA can be done through the use of circulating tumor (ct) DNA sequencing, which may help to target specific mutations and improve treatment selection for this rare type of cancer. Read More ›
Oral Parity Laws Could Reduce Disparities in Cancer Care
Oral Parity Laws Could Reduce Disparities in Cancer Care
By Chase Doyle
Healthcare Policy
TON - December 2019, Vol 12, No 6
San Diego, CA—Great progress has been made in the fight against cancer, but not all patients have benefited equally. Disparities exist among specific populations in terms of survival and cancer-related mortality, incidence and prevalence, as well as adverse health conditions, according to Karen M. Winkfield, MD, PhD, Director, Office of Cancer Health Equity, Wake Forest Baptist Medical Center Comprehensive Cancer Center, Winston-Salem, NC. Dr Winkfield discussed the topic at the 2019 ASCO Quality Care Symposium. Read More ›
FDA News
FDA Updates
TON - December 2019, Vol 12, No 6

This section provides a brief overview of new cancer drugs or new indications approved by the FDA between November 14 and November 21, 2019.

  • Brukinsa Receives FDA Approval for Patients with Mantle-Cell Lymphoma
  • FDA Approves Adakveo to Reduce Vaso-Occlusive Crises in Patients with Sickle-Cell Disease
  • Calquence Receives FDA Approval for the Treatment of Patients with CLL or SLL
Read More ›
FDA Grants Priority Review to Keytruda for Patients with High-Risk, Non–Muscle-Invasive Bladder Cancer
Bladder Cancer, FDA Updates, Immunotherapy
Web Exclusives
The FDA has granted priority review to Merck’s supplemental Biologics License Application for the anti-PD–1 agent pembrolizumab as monotherapy for certain patients with high-risk, non-muscle invasive bladder cancer who are ineligible for or have elected not to undergo cystectomy. Read More ›
Inrebic Receives FDA Approval for Adults with Myelofibrosis
FDA Updates
Web Exclusives
On August 16, 2019, the FDA approved fedratinib (Inrebic; Celgene/Impact Biomedicines), an oral kinase inhibitor, for adults with intermediate-2 or high-risk primary or secondary—post–polycythemia vera (PV) or post–essential thrombocythemia (ET)—myelofibrosis, a rare bone marrow disorder. The FDA granted fedratinib priority review and an orphan drug designation. Read More ›
FDA Approved Erleada for Metastatic Castration-Sensitive Prostate Cancer
FDA Updates
Web Exclusives
On September 17, 2019, the FDA approved a new indication for apalu­tamide (Erleada; Janssen Biotech) for the treatment of patients with metastatic castration-sensitive prostate cancer (CSPC). Apalutamide was initially approved in 2018 for the treatment of nonmetastatic castration-resistant prostate cancer. The FDA granted apalutamide priority review for the new indication. Read More ›
Keytruda plus Lenvima Combo FDA Approved for Advanced Endometrial Carcinoma with No MSI-H or dMMR Tumors
FDA Updates
Web Exclusives
On September 17, 2019, the FDA accelerated the approval of a new combination of pembrolizumab (Keytruda; Merck) plus lenvatinib (Lenvima; Eisai) for patients with advanced endometrial carcinoma that is not associated with microsatellite instability high (MSI-H) or mismatch repair–deficient (dMMR) tumors in patients whose disease progressed after systemic therapy and who are candidates for curative surgery or radiation. The FDA granted this application priority review and a breakthrough therapy designation. Read More ›
Long-Term Data Confirm Survival Benefit for Pembrolizumab in Advanced NSCLC
By Phoebe Starr
Lung Cancer
Web Exclusives
Chicago, IL—Treatment with the immune checkpoint inhibitor pembroliz­umab (Keytruda) dramatically improved 5-year survival for patients with advanced non–small-cell lung cancer (NSCLC) compared with expected survival in the preimmunotherapy era, according to the 5-year follow-up data from the phase 1b KEYNOTE-001 clinical trial. The study was presented at ASCO 2019 and was published simultaneously in the Journal of Clinical Oncology. Read More ›
The Burden of Ovarian Cancer Affects Multiple Dimensions of Women's Lives
Ovarian Cancer
Web Exclusives
Ovarian cancer not only exacts a high mortality rate, but also affects the physical, mental, and financial health of those diagnosed with the disease. Read More ›

Page 141 of 376


Subscribe Today!

To sign up for our newsletter or print publications, please enter your contact information below.

I'd like to receive:

Sign Up for The Oncology Nurse®‑APN/PA

Subscribe to receive the free, TON print publication, and TON Bi-Weekly e‑newsletter.

Subscribe

Amplity

© Amplity, Inc. All Rights Reserved. Privacy Policy.